Immunomet Therapeutics Is A Clinical Stage Biotech Targeting Cellular Metabolism To Develop Novel Anti Fibrotic And Anti Tumor Therapiesour Lead Moleculeim156Is A Protein Complex 1Pc1Inhibitor That Targets The Oxidative Phosphorylationoxphospathway In Mitochondria And Decreases Aberrant Cell Growth In Fibrosis And Select Cancer Cellsim156 Is The First Potent Pc1 Inhibitor To Complete Phase 1 With A Good Tolerabilityin Fibrosisimmunomet Is Currently Conducting A Phase 1 Study In Healthy Volunteers And Plan To Progress Into Phase 2 Poc Study In Ipf Patients In 4Q2021The Company Was Founded In 2015Is A Spin Off From Hanall Biopharmaa Korean Midsized Public Companyand Has Raised $31 Mm Post Spin Off
